Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 3/20 | 0.80 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.80 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.80 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.80 |
| ▸ | FAAH | O00519 | 3/20 | 0.69 |
| ▸ | CNR1 | P21554 | 2/20 | 0.69 |
| ▸ | CNR2 | P34972 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | SELP | P16109 | 1/20 | 0.68 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | DGKA | P23743 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17438587 | 1.00 | PRKCA (0.80) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| SCHEMBL599863 | 0.96 | PRKCA (0.85) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| SCHEMBL10064876 | 0.94 | PRKCA (0.90) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| SCHEMBL16431079 | 0.93 | PRKCA (0.92) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| SCHEMBL10492136 | 0.93 | PRKCA (0.92) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| SCHEMBL3181278 | 0.93 | PRKCA (0.92) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| SCHEMBL19564925 | 0.93 | PRKCA (0.92) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| SCHEMBL2477265 | 0.93 | PRKCA (0.92) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| SCHEMBL1879786 | 0.93 | PRKCA (0.92) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| SCHEMBL3182554 | 0.93 | PRKCA (0.92) | PRKCAPRKCEPRKCQPRKCDFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3153163-B1 | PHARMACEUTICAL COMPOUND COMPRISING 13 GLYCERIDES, FORMULATION AND APPLICATION THEREOF | ZHEJIANG KANGLAITE GROUP CO LTD (CN) | 2019-05-22 | — | — | EP | disclosed |
| US-9884037-B2 | Pharmaceutical composition containing 8 triglycerides, and preparations and use thereof | Zhejiang Kanglaite Group Co., Ltd. (CN) | 2018-02-06 | — | — | US | disclosed |
| EP-3153163-A1 | PHARMACEUTICAL COMPOUND COMPRISING 13 GLYCERIDES, FORMULATION AND APPLICATION THEREOF | Zhejiang Kanglaite Group Co. Ltd. (CN) | 2017-04-12 | — | — | EP | disclosed |
| US-9585858-B2 | Pharmaceutical composition containing 13 triglycerides, and preparations and use thereof | Zhejiang Kanglaite Group Co., Ltd. (CN) | 2017-03-07 | — | — | US | disclosed |
| US-20160015670-A1 | COMPOUND, 1-PALMITIN-2-LINOLEIN-3-OLEIN, AND PHARMACEUTICAL PREPARATION AND USE THEREOF | Zhejiang Kanglaite Group Co., Ltd. (CN) | 2016-01-21 | — | — | US | disclosed |
| US-20160015672-A1 | PHARMACEUTICAL COMPOSITION CONTAINING 13 TRIGLYCERIDES, AND PREPARATIONS AND USE THEREOF | ZHEJIANG KANGLAITE PHARMACEUTICAL CO., LTD. (CN) | 2016-01-21 | — | — | US | disclosed |
| US-20160015669-A1 | COMPOUND, 1, 3-DIOLEIN-2-LINOLEIN, AND PHARMACEUTICAL PREPARATION AND USE THEREOF | Zhejiang Kanglaite Group Co., Ltd. (CN) | 2016-01-21 | — | — | US | disclosed |
| US-20160015671-A1 | PHARMACEUTICAL COMPOSITION CONTAINING 8 TRIGLYCERIDES, AND PREPARATIONS AND USE THEREOF | ZHEJIANG KANGLAITE PHARMACEUTICAL CO., LTD. (CN) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015670-A1 | COMPOUND, 1-PALMITIN-2-LINOLEIN-3-OLEIN, AND PHARMACEUTICAL PREPARATION AND USE THEREOF | PLIN3, PLIN1, ALOX12 | PRKCA 3678/4885PRKCE 3992/4885PRKCQ 3103/4885 |
| US-20160015669-A1 | COMPOUND, 1, 3-DIOLEIN-2-LINOLEIN, AND PHARMACEUTICAL PREPARATION AND USE THEREOF | BROX, SNX1, SNX2 | PRKCA 4508/4885PRKCE 4704/4885PRKCQ 4352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.